Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease

Abstract

Aim:To evaluate the anti-inflammatory effect of antiplatelet agent, clopidogrel, in experimentally induced inflammatory bowel disease (IBD).Materials and Methods:TNBS induced Crohn's disease model and oxazolone induced ulcerative colitis model were used to evaluate the role of clopidogrel in IBD. Spargue Dawley female and Wistar male rats were used respectively. The colitis was induced by a single intra-colonic application of TNBS (0.25 ml, 120 mg/ml in 50% ethanol) and oxazolone (450 μl 5% oxazolone in 50% ethanol). Rats were divided into four groups (n=6) in each model namely normal control, sham control, test and standard group. Drug treatment was carried out for 21 days. After 21 days, animals were sacrificed and evaluated for weight change, colon mucosal damage index (CMDI), disease activity Index (DAI) and myeloperoxidase (MPO) activity.Results:Results showed that clopidogrel provided significant protection against mucosal damage in both the models of IBD. It significantly reduced (P<0.05) the decrease in body weight and CMDI, DAI and MPO scores.Conclusion:The results indicate that clopidogrel may be effective in treatment of Crohn's disease and ulcerative colitis. Platelet inhibition may be one of the mechanism for effectiveness of clopidogrel in the treatment of IBD.

Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation

“…Statin use was associated with a significantly decreased risk of IBD (OR: 0.68, 95%CI: 0.64-0.72), CD (OR: 0.64, 95%CI: 0.59-0.71), and UC (OR: 0.70, 95%CI: 0.65-0.76)[ 43 ]. Two studies developed animal models of IBD by chemically inducing CD and UC and showed that captopril was implicated in reducing transforming growth factor-beta1 expression and colitis-associated fibrosis[ 44 , 58 ]. Clopidogrel also reduced disease activity index and colonic mucosal damage index in mice – thus providing an additional link between treatment of IBD and ASCVD[ 58 ].…”

The Inflammatory Role of Platelets: Translational Insights from Experimental Studies of Autoimmune Disorders

“…Nonetheless, blockade of GPIIb/IIIa had no effect on platelet adhesion in an experimental model of colitis [82]. In contrast to RA, pharmacological blockade of P2Y 12 receptor by clopidogrel or treatment with acetylsalicylic acid reveals an attenuated disease course in models of IBD [98,99]. …”

Drug Repurposing in Crohn’s Disease Using Danish Real-World Data

“…Earlier research indicated that clopidogrel enhanced the inhibition of platelet activation, platelet-leukocyte interaction, and P-selectin expression on CD40 lymphocytes through P2Y12 receptor inhibition, which might contribute to the resolution of IBD symptoms. 48 …”